Literature DB >> 26487913

Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.

Vibha Tandon1, Pooja Yadav2, Souvik Sur2, Sheenu Abbat3, Vinod Tiwari2, Raymond Hewer4, Maria A Papathanasopoulos5, Rameez Raja6, Akhil C Banerjea6, Akhilesh K Verma2, Shrikant Kukreti2, Prasad V Bharatam3.   

Abstract

6-Endo-dig-cyclization is an efficient method for the synthesis of 1,2-dihydroisoquinolines. We have synthesized few 1,2-dihydroisoquinolines having different functionality at the C-1, C-3, C-7, and N-2 positions for evaluation against HIV-1 integrase (HIV1-IN) inhibitory activity. A direct nitro-Mannich condensation of o-alkynylaldimines and dual activation of o-alkynyl aldehydes by inexpensive cobalt chloride yielded desired compounds. Out of 24 compounds, 4m and 6c came out as potent integrase inhibitors in in vitro strand transfer (ST) assay, with IC50 value of 0.7 and 0.8 μM, respectively. Molecular docking of these compounds in integrase revealed strong interaction between metal and ligands, which stabilizes the enzyme-inhibitor complex. The ten most active compounds were subjected to antiviral assay. Out of those, 6c reduced the level of p24 viral antigen by 91%, which is comparable to RAL in antiviral assay. Interestingly, these compounds showed similar ST inhibitory activity in G140S mutant, suggesting they can act against resistant strains.

Entities:  

Keywords:  Multicomponent reaction; integrase; integrase inhibitors; molecular docking

Year:  2015        PMID: 26487913      PMCID: PMC4601057          DOI: 10.1021/acsmedchemlett.5b00230

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  31 in total

1.  Lewis acid- and organocatalyst-cocatalyzed multicomponent reactions of 2-alkynylbenzaldehydes, amines, and ketones.

Authors:  Qiuping Ding; Jie Wu
Journal:  Org Lett       Date:  2007-10-26       Impact factor: 6.005

Review 2.  Retroviral integrases and their cousins.

Authors:  P Rice; R Craigie; D R Davies
Journal:  Curr Opin Struct Biol       Date:  1996-02       Impact factor: 6.809

Review 3.  Integrase inhibitors to treat HIV/AIDS.

Authors:  Yves Pommier; Allison A Johnson; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2005-03       Impact factor: 84.694

4.  Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

Authors:  Filippo Canducci; Elisa R Ceresola; Enzo Boeri; Vincenzo Spagnuolo; Francesca Cossarini; Antonella Castagna; Adriano Lazzarin; Massimo Clementi
Journal:  J Infect Dis       Date:  2011-10-07       Impact factor: 5.226

5.  Solution-phase parallel synthesis of a diverse library of 1,2-dihydroisoquinolines.

Authors:  Nataliya A Markina; Raffaella Mancuso; Benjamin Neuenswander; Gerald H Lushington; Richard C Larock
Journal:  ACS Comb Sci       Date:  2011-03-16       Impact factor: 3.784

6.  Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.

Authors:  Virginie Suchaud; Fabrice Bailly; Cedric Lion; Christina Calmels; Marie-Line Andréola; Frauke Christ; Zeger Debyser; Philippe Cotelle
Journal:  J Med Chem       Date:  2014-05-14       Impact factor: 7.446

7.  Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

Authors:  Kavya Ramkumar; Nouri Neamati
Journal:  Core Evid       Date:  2010-06-15

Review 8.  Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.

Authors:  Luis Menéndez-Arias
Journal:  Antiviral Res       Date:  2013-02-08       Impact factor: 5.970

9.  Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors.

Authors:  Klaus Klumpp; Julie Qi Hang; Surendran Rajendran; Yanli Yang; Andre Derosier; Philippe Wong Kai In; Hilary Overton; Kevin E B Parkes; Nick Cammack; Joseph A Martin
Journal:  Nucleic Acids Res       Date:  2003-12-01       Impact factor: 16.971

10.  The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors.

Authors:  H Akari; S Bour; S Kao; A Adachi; K Strebel
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

View more
  2 in total

1.  Editorial: Medicinal Chemistry Research in India.

Authors:  Ram Vishwakarma
Journal:  ACS Med Chem Lett       Date:  2017-03-09       Impact factor: 4.345

Review 2.  Development of Azaindole-Based Frameworks as Potential Antiviral Agents and Their Future Perspectives.

Authors:  J B Senthil Kumar; Parthasarathi Das; Vibha Tandon
Journal:  J Med Chem       Date:  2022-04-28       Impact factor: 8.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.